COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,082 Articles (22,658 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 1215: Articles 12141-12150  | Next

Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
Miller, R. A., Guru, P., Bauer, P., Robles, J., Tomaszewski, C., Overcash, J. S., Waters, M., Cameron, M., Olalla Sierra, J., Janc, J., Rudnick, J. A., Hu, S., Jones, W. B., Kwei, L., Mahabhashyam, S., Willingham, S. B., Criner, G.
10.1101/2021.09.13.21263406 — Posted: 2021-09-21
Effectiveness of vaccination in preventing severe SARS CoV-2 infection in South India-a hospital based cross sectional study
ruban, A. c. p., Mohamed, A., Kalyanaraman, S.
10.1101/2021.09.17.21263670 — Posted: 2021-09-21
Prior Covid-19 and high RBD-IgG levels correlate with protection against VOC-delta SARS-CoV-2 infection in vaccinated Nursing Home Residents
Blain, H., TUAILLON, E., Pisoni, A., Soriteau, L., Million, E., Leglise, M.-S., Bussereau, I., Miot, S., Rolland, Y., Picot, M.-C., Bousquet, J. J.
10.1101/2021.09.21.21263880 — Posted: 2021-09-21
An epi-evolutionary model to predict spore-producing pathogens adaptation to quantitative resistance in heterogeneous environments
Fabre, F., Burie, J.-B., Ducrot, A., Lion, S., Richard, Q., Djidjou-Demasse, R.
10.1101/423467 — Posted: 2021-09-21
Real-world serologic responses to Extended-interval and Heterologous COVID-19 mRNA vaccination in Frail Elderly - Interim report from a prospective observational cohort study
Vinh, D. C., Gouin, J.-P., Cruz-Santiago, D., Canac-Marquis, M., Bernier, S., Bobeuf, F., Sengupta, A., Brassard, J.-P., Guerra, A., Dziarmaga, R., Perez, A., Sun, Y., Li, Y., Roussel, L., Langelier, M., Ke, D., Arnold, C., Pelchat, M., Langlois, M.-A., Evans, T. G., Zhang, X., Mazer, B. D.
10.1101/2021.09.16.21263704 — Posted: 2021-09-21
Computational systematics of nutritional support of vaccination against viral and bacterial pathogens as prolegomena to vaccinations against COVID-19
Torshin, I. Y., Gromova, O. A., Chuchalin, A. G.
10.1101/2021.09.10.21263398 — Posted: 2021-09-21
Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK
Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Chand, M., Brown, K., Ladhani, S., Ramsay, M., Lopez Bernal, J.
10.1101/2021.09.15.21263583 — Posted: 2021-09-21
A method to reduce ELISA serial dilution assay workload applied to SARS-CoV-2 and seasonal HCoVs
Pattinson, D., Jester, P., Guan, L., Yamayoshi, S., Chiba, S., Presler, R., Rao, H., Iwatsuki-Horimoto, K., Hagihara, M., Ikeda, N., Uchida, T., Mitamura, K., Halfmann, P., Neumann, G., Kawaoka, Y.
10.1101/2021.09.13.21263523 — Posted: 2021-09-21
COVID-19 epidemics monitored through the logarithmic growth rate and SIR model
Konishi, T.
10.1101/2021.09.13.21263483 — Posted: 2021-09-21
Characteristics and outcomes of an international cohort of 400,000 hospitalised patients with Covid-19
ISARIC Clinical Characterisation Group, , Kartsonaki, C.
10.1101/2021.09.11.21263419 — Posted: 2021-09-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).